Drug Trial Radar · NCT01630083
Efficacy and Safety of IMAB362 in Combination With the EOX Regimen for CLDN18.2-positive Gastric Cancer
Last checked: Nov 20, 2026Latest source record: Jun 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
252
Actual
Start
Jul 19, 2012
Primary completion
Jan 31, 2019
Study completion Jan 31, 2019
Sponsor
- Lead sponsor
- Astellas Pharma Global Development, Inc.Astellas (ALPMY)
- Sponsor type
- Industry
- First posted
- Jun 28, 2012
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the trial is to assess the therapeutic effects and the safety profile of IMAB362 combined with EOX (epirubicin, oxaliplatin, capecitabine) as first-line treatment for patients with advanced adenocarcinoma of the stomach, the esophagus or the gastroesophageal junction compared to EOX alone. Furthermore, sufficient binding of IMAB362 to the target cells is necessary for antitumoral activity. Thus, two dose levels ensuring a serum level above the in vitro predicted clinical efficacy threshold will be investigated.
Conditions
- CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction
- CLDN18.2-positive Adenocarcinoma of Esophagus
- CLDN18.2-positive Gastric Adenocarcinoma
Interventions
epirubicinDrug
Epirubicin will be administered at a dose of 50 mg/m\^2 as a 15-minute intravenous infusion on day 1 of each cycle.
oxaliplatinDrug
Oxaliplatin will be administered at a dose of 130 mg/m\^2 as a 2-hour intravenous infusion on day 1 of each cycle.
capecitabineDrug
The daily dose of capecitabine will be 1250 mg/m\^2. Capecitabine tablets to be given once daily at a dose of 625 mg/m\^2 orally in the evening of day 1 of each cycle and twice daily at a dose of 625 mg/m\^2 orally on days 2 to 21 of each cycle; the morning dose of capecitabine on day 1 of each cycle to be omitted due to administration of zolbetuximab, epirubicin and oxaliplatin.
zolbetuximabDrug
Two different formats of zolbetuximab, comprising different strengths, to be provided. Vials contained 22 mg or 105 mg of zolbetuximab. Prior to administration, zolbetuximab will be reconstituted with 1.1 mL (22 mg zolbetuximab vials) or 5.0 mL (105 mg zolbetuximab vials) water for injection, which will result in a concentration of 20 mg/mL zolbetuximab. The extractable volume per vial will be 1 mL (for 22 mg zolbetuximab vials) or 5 mL (for 105 mg zolbetuximab vials). The reconstituted solution will be further diluted with sodium chloride 0.9% to a final concentration of 2 mg/mL zolbetuximab. Zolbetuximab will be administered as an intravenous infusion over 2 to 3 hours.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survival (PFS)Time frame: From randomization to the data cut-off date of 31JAN2019; maximum time on follow-up was, 68.2, 47.2 & 59.6 months in the EOX, EOX+Zolbetuximab 600 mg, and EOX+Zolbetuximab 1000 mg treatment groups respectively.
- Number of Participants with Adverse Events (AEs)Time frame: From the first dose of study drug administration up to 30 days after the last study medication administration (up to 1791 days).
Locations
48 sites in 6 countries. Site status is shown where the registry gives one.
Site BUL004
Plovdiv, Bulgaria
Site BUL001
Sofia, Bulgaria
Site BUL003
Sofia, Bulgaria
Site BUL005
Sofia, Bulgaria
Site BUL002
Varna, Bulgaria
Site CZE002
Olomouc, Czechia
Site CZE001
Znojmo, Czechia
Site GER012
Bielefeld, Germany
Site GER029-01
Bochum, Germany
Site GER029
Bochum, Germany
Site GER010
Dresden, Germany
Site GER001
Essen, Germany
Site GER017
Frankfurt, Germany
Site GER005
Halle, Germany
Site GER020
Leipzig, Germany
Site GER016
Münster, Germany
Site GER013
Pinneberg, Germany
Site LAT001
Liepāja, Latvia
Site LAT002
Riga, Latvia
Site RUS011
Arkhangelsk, Russia
Site RUS016
Bryansk, Russia
Site RUS006
Chelyabinsk, Russia
Site RUS007
Ivanovo, Russia
Site RUS009
Kursk, Russia
Site RUS001
Moscow, Russia
Site RUS002
Obninsk, Russia
Site RUS023
Omsk, Russia
Site RUS014
Orenburg, Russia
Site RUS012
Oryol, Russia
Site RUS005
Pyatigorsk, Russia
Site RUS019
Ryazan, Russia
Site RUS003
Saint Petersburg, Russia
Site RUS010
Saint Petersburg, Russia
Site RUS015
Saint Petersburg, Russia
Site RUS017
Velikiy Novgorod, Russia
Site RUS013
Yaroslavl, Russia
Site UKR003
Dnipropetrovsk, Ukraine
Site UKR001
Donetsk, Ukraine
Site UKR002
Donetsk, Ukraine
Site UKR008
Ivano-Frankivsk, Ukraine
Showing 40 of 48 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.